semaglutide/cyanocobalamin Compound Semaglutide GLP-1 (Semaglutide) Program

NICE guidance (TA875) supports the use of semaglutide 2.4 mg (Wegovy) for adults with a BMI of 35 kg/m or above alongside at least one weight-related condition, within a specialist weight management service (with lower BMI thresholds applicable for certain ethnic groups and other commissioning criteria)

Some patients benefit from eating smaller amounts more frequently during peak fatigue periods

Understanding how to use this medication effectively, combined with behavioral changes and proper monitoring, maximizes your chances of achieving meaningful and sustainable weight loss

Access disparities exist, with studies suggesting lower utilization rates among Black, Hispanic, and other minority populations despite higher rates of diabetes and obesity in these communities

Age Older adults generally clear medications more slowly due to age-related changes in kidney function and metabolism

295 , E1323E1332 (2008)